HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Relaxation Potion Warning: Wake Up Call About FDA Beverage Guidance

This article was originally published in The Tan Sheet

Executive Summary

FDA warning letter on Dewmar’s Lean Slow Motion…Potion line is the first addressing differences between products marketed as conventional beverages and as liquid supplements since a final guidance in January. Attorney Justin Prochnow says the warning could signal an FDA crackdown on melatonin in conventional beverages.

You may also be interested in...



FDA Liquid Supplement/Beverage Guidance Defines Distinctions

The CFSAN guidance goes into greater detail on distinguishing liquid supplements from beverages, addressing stakeholders’ complaint about a 2009 draft. “This tends to really draw a bright line between the two different categories,” says CRN Regulatory Counsel Rend Al-Mondhiry.

Regulatory News In Brief

FDA fires warning shot on Breathable Foods’ “inhalable caffeine”; agency guidance advises against phthalate excipients in drugs; pandemic adverse event reporting guidance finalized; Globe All Wellness recall of tainted supplements is insufficient; more Regulatory News In Brief.

FDA's Drank Melatonin Warning Echoes Liquid Supplement Draft Guidance

FDA's warning to a firm marketing a melatonin-containing beverage yields early evidence of how the agency intends to enforce provisions of its draft guidance on liquid dietary supplements

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS139782

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel